Polydex Pharmaceuticals Ltd. (PN) (USOTC:POLXF)
Historical Stock Chart
5 Years : From Oct 2010 to Oct 2015
Polydex Pharmaceuticals Limited (Pink Sheets:POLXF) (the "Company") is pleased to announce the launch of a newly updated company website at www.Polydex.com.
The new, simpler website provides an introduction to the Company, provides access to recent news releases and other company information as it becomes available, and includes links to current stock quotes and charts. Shareholders and visitors can also now subscribe to receive News Releases directly from the Company website.
The Company has also recently launched a new website at www.Dextran.ca highlighting its core-product line, production facilities, company history and management.
The Company shares continue to be quoted on the Pink Sheet platform (www.pinksheets.com).
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market, and also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry.
The Polydex Pharmaceuticals Limited logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3414
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like "may," "could," "might," "expect," "anticipate," "believe," or similar words. Actual events or results may differ materially from the Company's expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company's filings with the United States Securities and Exchange Commission may also affect the actual results achieved by the Company.
CONTACT: Investor Relations:
North Arm Capital Services